Studies have also shown that in LNCaP prostate cancer xenografts mouse models, TAK-441 delayed castration-resistant progression of the disease and significantly suppressed GLI1, GLI2, and PTCH1 gene expression. This evidence concerns the gene PTCH1 and prostate carcinoma.